CalciMedica’s (CALC) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of CalciMedica (NASDAQ:CALC) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $16.00 price target on the stock.

CalciMedica Stock Up 3.3 %

Shares of CALC stock opened at $2.20 on Tuesday. CalciMedica has a 12 month low of $1.86 and a 12 month high of $6.27. The stock has a 50-day moving average price of $2.75 and a 200 day moving average price of $3.43. The firm has a market cap of $29.66 million, a price-to-earnings ratio of -2.04 and a beta of 1.20.

Institutional Investors Weigh In On CalciMedica

A number of institutional investors have recently made changes to their positions in CALC. Cetera Investment Advisers increased its position in shares of CalciMedica by 37.1% in the 4th quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock valued at $60,000 after buying an additional 4,566 shares in the last quarter. Atria Investments Inc grew its position in shares of CalciMedica by 28.3% in the 4th quarter. Atria Investments Inc now owns 34,012 shares of the company’s stock valued at $120,000 after purchasing an additional 7,509 shares during the period. PVG Asset Management Corp bought a new stake in CalciMedica during the 3rd quarter worth approximately $67,000. Millennium Management LLC raised its holdings in CalciMedica by 30.5% during the 4th quarter. Millennium Management LLC now owns 72,057 shares of the company’s stock worth $255,000 after buying an additional 16,824 shares during the period. Finally, Geode Capital Management LLC lifted its stake in CalciMedica by 51.2% in the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after buying an additional 22,525 shares in the last quarter.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.